Previous Close | 0.0800 |
Open | 0.0800 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 0.50 |
Expire Date | 2025-01-17 |
Day's Range | 0.0800 - 0.0800 |
Contract Range | N/A |
Volume | |
Open Interest | 569 |
Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.
Revenue Declines Amidst Generic Competition, Yet Strategic Initiatives Show Promise
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host